# Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.

> **NCT00752609** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 102 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** Peginesatide

## Key facts

- **NCT ID:** NCT00752609
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2012-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00752609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00752609, "Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00752609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*